Objectives & Focus of Discussions

Objectives:

• Outline key elements of the Legacy Planning process
• Seek input /guidance into the process

Focus of Today’s Discussions:

• Overall process and objectives: are we on the right track?
• Do the planned consultations capture everyone who should be consulted?
• Who should oversee the Legacy Planning process, and how?
**Main Elements of Legacy Planning: Objective 4 of the GPEI ‘Eradication and Endgame Strategic Plan’**

**Purpose:** “Ensure that the world remains polio-free and that the investment in polio eradication provides public health dividends for years to come”

**Main Elements:**

<table>
<thead>
<tr>
<th>1. Mainstream essential long-term polio functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Capture and share lessons learned during over 20 years of eradication</td>
</tr>
<tr>
<td>3. Transition programme assets, as appropriate, to benefit other health priorities</td>
</tr>
</tbody>
</table>
In thinking through Polio Legacy Planning, considerations include:

- Polio programme’s Strengths and Weaknesses
- Other health priorities
- Areas that can be built on for other health and development goals
  - Knowledge and Lessons Learned
  - Tangible Assets (systems, processes, HR, infrastructure)
- Oversight and decision-making on the Legacy
Initial thinking on Legacy suggests:

**The Polio programme has a unique ability to:**

- Reach unreached, chronically neglected and marginalized communities (with OPV and other health services such as Vitamin A, LLINs, anti-helminthics), through effective:
  - Mapping and micro-planning
  - Data collection and management
  - Social mobilization
  - Communications
  - Logistics and supply
  - Staff training, deployment and management
  - Field level monitoring

- **Conduct effective disease surveillance and response, reaching some of the most remote and underserved geographies in the world, including:**
  - AFP and environmental surveillance for polio
  - Vaccine-preventable diseases (e.g., measles, yellow fever, meningitis, etc.)
  - Humanitarian crises
  - Laboratory capacity
### Capturing & Sharing Knowledge and Lessons Learned

<table>
<thead>
<tr>
<th>Capture knowledge &amp; lessons learned</th>
<th>In four main areas:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Policy and strategy</td>
<td>1. Policy and strategy</td>
</tr>
<tr>
<td>2. Partnerships and coordination</td>
<td>2. Partnerships and coordination</td>
</tr>
<tr>
<td>3. Operations and tactics</td>
<td>3. Operations and tactics</td>
</tr>
<tr>
<td>4. Oversight and monitoring</td>
<td>4. Oversight and monitoring</td>
</tr>
</tbody>
</table>

### Process for sharing Knowledge and Lessons Learned: to be defined

<table>
<thead>
<tr>
<th>Asset mapping (to guide Legacy planning process)</th>
<th>1. Outline and characterize existing assets</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. Establish what functions polio-funded assets/staff contribute</td>
</tr>
<tr>
<td></td>
<td>3. Determine what capacities could be at risk with programme closure</td>
</tr>
<tr>
<td></td>
<td>4. Quantify the financial, managerial resources required to support each asset</td>
</tr>
</tbody>
</table>
Consultations

Proposed consultations:

• National Governments, through WHO Regional Committees

• Major Stakeholders and Donors
  ➢ Polio and non-Polio

• Global health initiatives:
  ➢ GAVI
  ➢ MRI
  ➢ Global Fund
  ➢ Others?

• Academia/Public Health Experts

*Draw on lessons learned from other initiative development (e.g. Global Vaccine Action Plan)*
Management & Oversight of Legacy Planning

Management Considerations

- Minimize distraction from core eradication focus
- Sufficiently broad engagement to facilitate agreement and ensure long-term success

Oversight

- Polio Oversight Board with Polio Partners Group
- Or is another structure needed (e.g. an independent commission)?

An appropriate decision-making body for the Legacy Strategic Plan

- World Health Assembly

Are there best practices/examples that we can draw from?

<table>
<thead>
<tr>
<th>ACTIVITY</th>
<th>TIMEFRAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAGE, Geneva</td>
<td>9 April</td>
</tr>
<tr>
<td>PPG, Geneva</td>
<td>10 April</td>
</tr>
<tr>
<td>GPMT and GPEI Partners meeting, Geneva</td>
<td>12-14 June</td>
</tr>
<tr>
<td>WHO Regional Committee Consultations</td>
<td>2013-2014</td>
</tr>
<tr>
<td>Consultations with Major Initiatives and Donors</td>
<td>2013-2014</td>
</tr>
<tr>
<td>World Health Assembly</td>
<td>May 2014</td>
</tr>
<tr>
<td>Legacy Strategic Plan Development</td>
<td>2014-15</td>
</tr>
<tr>
<td><em>Final Plan by end-2015</em></td>
<td></td>
</tr>
</tbody>
</table>
Key Questions:

• Overall process and objectives: are we on the right track?

• Do the planned consultations capture everyone who should be consulted?

• Who should oversee the Legacy Planning process, and how?